Galena Biopharma Inc., of Portland, Ore., said it had executed a purchase agreement for up to $55 million with Lincoln Park Capital Fund LLC. The fund initially purchased $5 million of the company's common stock at $2 per share, a premium of 9 percent on market close stock price as of Nov. 18.